nodes	percent_of_prediction	percent_of_DWPC	metapath
Primidone—CYP2B6—Sorafenib—thyroid cancer	0.161	0.195	CbGbCtD
Primidone—CYP2C8—Sorafenib—thyroid cancer	0.122	0.148	CbGbCtD
Primidone—CYP2C19—Sorafenib—thyroid cancer	0.102	0.124	CbGbCtD
Primidone—CYP2B6—Doxorubicin—thyroid cancer	0.0976	0.119	CbGbCtD
Primidone—CYP1A2—Sorafenib—thyroid cancer	0.0943	0.115	CbGbCtD
Primidone—CYP2C9—Sorafenib—thyroid cancer	0.085	0.103	CbGbCtD
Primidone—CYP3A4—Vandetanib—thyroid cancer	0.082	0.0996	CbGbCtD
Primidone—CYP3A4—Sorafenib—thyroid cancer	0.0494	0.06	CbGbCtD
Primidone—CYP3A4—Doxorubicin—thyroid cancer	0.03	0.0364	CbGbCtD
Primidone—Depression—Vandetanib—thyroid cancer	0.00436	0.0308	CcSEcCtD
Primidone—Visual impairment—Vandetanib—thyroid cancer	0.00378	0.0267	CcSEcCtD
Primidone—GABRA3—neck—thyroid cancer	0.00368	0.104	CbGeAlD
Primidone—Eye disorder—Vandetanib—thyroid cancer	0.00367	0.0259	CcSEcCtD
Primidone—Mental disorder—Vandetanib—thyroid cancer	0.00344	0.0243	CcSEcCtD
Primidone—Malnutrition—Vandetanib—thyroid cancer	0.00341	0.0242	CcSEcCtD
Primidone—Eruption—Epirubicin—thyroid cancer	0.00317	0.0224	CcSEcCtD
Primidone—CHRNA7—neck—thyroid cancer	0.0031	0.088	CbGeAlD
Primidone—Eruption—Doxorubicin—thyroid cancer	0.00293	0.0207	CcSEcCtD
Primidone—Arthralgia—Vandetanib—thyroid cancer	0.00291	0.0206	CcSEcCtD
Primidone—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00289	0.0204	CcSEcCtD
Primidone—Nervous system disorder—Vandetanib—thyroid cancer	0.00273	0.0193	CcSEcCtD
Primidone—Nystagmus—Epirubicin—thyroid cancer	0.00273	0.0193	CcSEcCtD
Primidone—Skin disorder—Vandetanib—thyroid cancer	0.00271	0.0191	CcSEcCtD
Primidone—Connective tissue disorder—Sorafenib—thyroid cancer	0.0026	0.0184	CcSEcCtD
Primidone—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00254	0.018	CcSEcCtD
Primidone—Nystagmus—Doxorubicin—thyroid cancer	0.00252	0.0178	CcSEcCtD
Primidone—Decreased appetite—Vandetanib—thyroid cancer	0.00242	0.0171	CcSEcCtD
Primidone—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00241	0.017	CcSEcCtD
Primidone—Fatigue—Vandetanib—thyroid cancer	0.0024	0.017	CcSEcCtD
Primidone—Blood disorder—Epirubicin—thyroid cancer	0.00233	0.0165	CcSEcCtD
Primidone—Mental disorder—Sorafenib—thyroid cancer	0.00232	0.0164	CcSEcCtD
Primidone—CHRFAM7A—trachea—thyroid cancer	0.00231	0.0655	CbGeAlD
Primidone—Malnutrition—Sorafenib—thyroid cancer	0.0023	0.0163	CcSEcCtD
Primidone—Blood disorder—Doxorubicin—thyroid cancer	0.00216	0.0153	CcSEcCtD
Primidone—Anaemia—Sorafenib—thyroid cancer	0.00213	0.0151	CcSEcCtD
Primidone—Asthenia—Vandetanib—thyroid cancer	0.002	0.0141	CcSEcCtD
Primidone—Arthralgia—Sorafenib—thyroid cancer	0.00196	0.0139	CcSEcCtD
Primidone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00195	0.0138	CcSEcCtD
Primidone—Nervous system disorder—Sorafenib—thyroid cancer	0.00184	0.013	CcSEcCtD
Primidone—Dizziness—Vandetanib—thyroid cancer	0.00184	0.013	CcSEcCtD
Primidone—CHRFAM7A—thyroid gland—thyroid cancer	0.00183	0.0519	CbGeAlD
Primidone—Skin disorder—Sorafenib—thyroid cancer	0.00183	0.0129	CcSEcCtD
Primidone—Anorexia—Sorafenib—thyroid cancer	0.00179	0.0127	CcSEcCtD
Primidone—GRIA2—head—thyroid cancer	0.00178	0.0505	CbGeAlD
Primidone—Vomiting—Vandetanib—thyroid cancer	0.00177	0.0125	CcSEcCtD
Primidone—Rash—Vandetanib—thyroid cancer	0.00176	0.0124	CcSEcCtD
Primidone—Dermatitis—Vandetanib—thyroid cancer	0.00176	0.0124	CcSEcCtD
Primidone—GABRA3—thyroid gland—thyroid cancer	0.00175	0.0497	CbGeAlD
Primidone—Headache—Vandetanib—thyroid cancer	0.00175	0.0123	CcSEcCtD
Primidone—GABRA6—head—thyroid cancer	0.00172	0.0488	CbGeAlD
Primidone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00171	0.0121	CcSEcCtD
Primidone—GABRA5—head—thyroid cancer	0.00167	0.0473	CbGeAlD
Primidone—Nausea—Vandetanib—thyroid cancer	0.00166	0.0117	CcSEcCtD
Primidone—Decreased appetite—Sorafenib—thyroid cancer	0.00163	0.0116	CcSEcCtD
Primidone—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00162	0.0115	CcSEcCtD
Primidone—CHRFAM7A—head—thyroid cancer	0.00162	0.046	CbGeAlD
Primidone—Fatigue—Sorafenib—thyroid cancer	0.00162	0.0115	CcSEcCtD
Primidone—GRIK2—head—thyroid cancer	0.00161	0.0456	CbGeAlD
Primidone—GABRA3—head—thyroid cancer	0.00155	0.0441	CbGeAlD
Primidone—GABRA4—head—thyroid cancer	0.00151	0.0429	CbGeAlD
Primidone—CHRNA7—thyroid gland—thyroid cancer	0.00148	0.0419	CbGeAlD
Primidone—Diplopia—Epirubicin—thyroid cancer	0.00141	0.01	CcSEcCtD
Primidone—Asthenia—Sorafenib—thyroid cancer	0.00135	0.00954	CcSEcCtD
Primidone—Ataxia—Epirubicin—thyroid cancer	0.00133	0.0094	CcSEcCtD
Primidone—CHRNA7—head—thyroid cancer	0.00131	0.0372	CbGeAlD
Primidone—Diplopia—Doxorubicin—thyroid cancer	0.00131	0.00925	CcSEcCtD
Primidone—CHRNA4—head—thyroid cancer	0.00129	0.0367	CbGeAlD
Primidone—GABRB2—head—thyroid cancer	0.00127	0.0359	CbGeAlD
Primidone—GABRG2—head—thyroid cancer	0.00127	0.0359	CbGeAlD
Primidone—Dizziness—Sorafenib—thyroid cancer	0.00124	0.00879	CcSEcCtD
Primidone—Ataxia—Doxorubicin—thyroid cancer	0.00123	0.0087	CcSEcCtD
Primidone—Vomiting—Sorafenib—thyroid cancer	0.0012	0.00845	CcSEcCtD
Primidone—Rash—Sorafenib—thyroid cancer	0.00119	0.00838	CcSEcCtD
Primidone—Dermatitis—Sorafenib—thyroid cancer	0.00118	0.00838	CcSEcCtD
Primidone—Headache—Sorafenib—thyroid cancer	0.00118	0.00833	CcSEcCtD
Primidone—GABRA2—head—thyroid cancer	0.00116	0.0328	CbGeAlD
Primidone—GABRA1—head—thyroid cancer	0.00112	0.0317	CbGeAlD
Primidone—Nausea—Sorafenib—thyroid cancer	0.00112	0.0079	CcSEcCtD
Primidone—Drowsiness—Epirubicin—thyroid cancer	0.00109	0.0077	CcSEcCtD
Primidone—Agranulocytosis—Epirubicin—thyroid cancer	0.00102	0.00719	CcSEcCtD
Primidone—Drowsiness—Doxorubicin—thyroid cancer	0.00101	0.00713	CcSEcCtD
Primidone—Connective tissue disorder—Epirubicin—thyroid cancer	0.000961	0.0068	CcSEcCtD
Primidone—Visual impairment—Epirubicin—thyroid cancer	0.000942	0.00667	CcSEcCtD
Primidone—Agranulocytosis—Doxorubicin—thyroid cancer	0.000941	0.00665	CcSEcCtD
Primidone—Eye disorder—Epirubicin—thyroid cancer	0.000914	0.00646	CcSEcCtD
Primidone—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000889	0.00629	CcSEcCtD
Primidone—Visual impairment—Doxorubicin—thyroid cancer	0.000872	0.00617	CcSEcCtD
Primidone—Mental disorder—Epirubicin—thyroid cancer	0.000857	0.00606	CcSEcCtD
Primidone—Malnutrition—Epirubicin—thyroid cancer	0.000851	0.00602	CcSEcCtD
Primidone—Eye disorder—Doxorubicin—thyroid cancer	0.000846	0.00598	CcSEcCtD
Primidone—GABRA2—lymph node—thyroid cancer	0.00081	0.023	CbGeAlD
Primidone—Mental disorder—Doxorubicin—thyroid cancer	0.000793	0.00561	CcSEcCtD
Primidone—Malnutrition—Doxorubicin—thyroid cancer	0.000788	0.00557	CcSEcCtD
Primidone—Anaemia—Epirubicin—thyroid cancer	0.000787	0.00556	CcSEcCtD
Primidone—CYP1A2—thyroid gland—thyroid cancer	0.000775	0.022	CbGeAlD
Primidone—Vertigo—Epirubicin—thyroid cancer	0.000765	0.00541	CcSEcCtD
Primidone—Anaemia—Doxorubicin—thyroid cancer	0.000728	0.00515	CcSEcCtD
Primidone—Arthralgia—Epirubicin—thyroid cancer	0.000725	0.00513	CcSEcCtD
Primidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00072	0.00509	CcSEcCtD
Primidone—Vertigo—Doxorubicin—thyroid cancer	0.000708	0.00501	CcSEcCtD
Primidone—Nervous system disorder—Epirubicin—thyroid cancer	0.000681	0.00482	CcSEcCtD
Primidone—Skin disorder—Epirubicin—thyroid cancer	0.000675	0.00477	CcSEcCtD
Primidone—Arthralgia—Doxorubicin—thyroid cancer	0.000671	0.00474	CcSEcCtD
Primidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000666	0.00471	CcSEcCtD
Primidone—Anorexia—Epirubicin—thyroid cancer	0.000662	0.00468	CcSEcCtD
Primidone—CYP2B6—head—thyroid cancer	0.000659	0.0187	CbGeAlD
Primidone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000633	0.00448	CcSEcCtD
Primidone—Nervous system disorder—Doxorubicin—thyroid cancer	0.00063	0.00446	CcSEcCtD
Primidone—Skin disorder—Doxorubicin—thyroid cancer	0.000624	0.00442	CcSEcCtD
Primidone—Somnolence—Epirubicin—thyroid cancer	0.000618	0.00437	CcSEcCtD
Primidone—Anorexia—Doxorubicin—thyroid cancer	0.000613	0.00433	CcSEcCtD
Primidone—Decreased appetite—Epirubicin—thyroid cancer	0.000604	0.00427	CcSEcCtD
Primidone—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.0006	0.00424	CcSEcCtD
Primidone—Fatigue—Epirubicin—thyroid cancer	0.000599	0.00424	CcSEcCtD
Primidone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000586	0.00414	CcSEcCtD
Primidone—Somnolence—Doxorubicin—thyroid cancer	0.000571	0.00404	CcSEcCtD
Primidone—Decreased appetite—Doxorubicin—thyroid cancer	0.000559	0.00395	CcSEcCtD
Primidone—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000555	0.00393	CcSEcCtD
Primidone—Fatigue—Doxorubicin—thyroid cancer	0.000554	0.00392	CcSEcCtD
Primidone—Asthenia—Epirubicin—thyroid cancer	0.000498	0.00353	CcSEcCtD
Primidone—Asthenia—Doxorubicin—thyroid cancer	0.000461	0.00326	CcSEcCtD
Primidone—Dizziness—Epirubicin—thyroid cancer	0.000459	0.00325	CcSEcCtD
Primidone—Vomiting—Epirubicin—thyroid cancer	0.000442	0.00312	CcSEcCtD
Primidone—Rash—Epirubicin—thyroid cancer	0.000438	0.0031	CcSEcCtD
Primidone—Dermatitis—Epirubicin—thyroid cancer	0.000438	0.0031	CcSEcCtD
Primidone—Headache—Epirubicin—thyroid cancer	0.000435	0.00308	CcSEcCtD
Primidone—Dizziness—Doxorubicin—thyroid cancer	0.000425	0.00301	CcSEcCtD
Primidone—Nausea—Epirubicin—thyroid cancer	0.000413	0.00292	CcSEcCtD
Primidone—Vomiting—Doxorubicin—thyroid cancer	0.000409	0.00289	CcSEcCtD
Primidone—Rash—Doxorubicin—thyroid cancer	0.000405	0.00287	CcSEcCtD
Primidone—Dermatitis—Doxorubicin—thyroid cancer	0.000405	0.00286	CcSEcCtD
Primidone—Headache—Doxorubicin—thyroid cancer	0.000403	0.00285	CcSEcCtD
Primidone—Nausea—Doxorubicin—thyroid cancer	0.000382	0.0027	CcSEcCtD
